T&K Introduction
Guangdong Taienkang Pharmaceutical Co., Ltd. (T&K) was founded in 1999 and is a comprehensive pharmaceutical enterprise (Stock Code 831173) engaged in R&D, production, sales and agent operation of pharmaceuticals/medical devices. Core products include "Fishingg Pill IV", "Aitingjiu" Dapoxetine Hydrochloride tablets, and "Jolethin" Lecithin Complex lodine tablets.Today the company has 6 wholly owned subsidiaries and 3 holding subsidiaries. T&K have operational outlets in 28 provincial regions across China and an international sales desk. This year, T&K have invested in setting up an operation within Europe, with its Headquarters situated in the vibrant heart of Central London.
Pharmaceutical R&D Base-- Shandong Hubble Kisen Biological Techonology Co., Ltd.
Shandong Hubble Kisen Biological Technology Co., Ltd., established in October 2015 as a wholly-owned subsidiary of Taienkang, is a high-tech drug research and development company staffed by over 90 professionals—including two PhDs, more than 20 master’s degree holders, and over 90% with bachelor’s degrees—working in a 6,500 sq.m. of new high-end RESEARCH and development laboratory and pilot workshop. The company’s vertically integrated “pyramid” model spans innovative chemical and biomacromolecule drugs at the top, improved new drugs and biotechnology platforms in the middle, and high-end generics at the base, supported by core technologies in functional excipients, nano delivery systems, biomacromolecule development, and consistency evaluation. With more than 30 drug candidates in development—including targeted antitumor and nano-micelle formulations, biopharmaceuticals, and distinctive generics—Hubble Kisen gained “High-tech Enterprise” status in 2019 and obtained one of China’s first Category B MAH production licenses in 2020. Its flagship product, Eterva (dapoxetine hydrochloride tablets), launched as the country’s first generic imitation and Shandong’s first MAH-approved drug, has achieved sales of over 15 million tablets, earning strong market recognition for its quality and efficacy.
APIs and Intermediates Manufacturer -- Sichuan Taienkang Pharmaceutical Co., Ltd.
T&K are working tirelessly to help produce face masks and other disposable PPE products for global consumers; hospitals; healthcare organisations and commercial businesses to help fight and combat Covid-19. Currently we produce over 5 Million face masks per day. We have class 100K clean workshops, sterile test rooms, positive control rooms & microbial limit rooms.
Internal Medicines -- Anhui Taienkang Pharmaceutical Co., Ltd.
Anhui Taienkang Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in the research, production, and marketing of oral solid formulations and medical devices. In 2012, it established its Bozhou Branch in Qiaocheng Economic Development Zone—Anhui’s medical hub—where modern facilities produce Chinese herbal pieces and refined TCM extracts. Operating six lines that produce over 30 types of tablets, granules, pills, and capsules (including the exclusive Compound Black Chicken Pill), the company has earned the status of a National High-Tech Enterprise, been designated as a Key Guarantee Enterprise for epidemic materials, and received Anhui Famous Trademark “Tianfukang,” along with multiple provincial and municipal awards for technological innovation and digital manufacturing. In collaboration with Wannan Medical College, Anhui University of Technology, and West Anhui College, Taienkang co-founded the Anhui Provincial Strategic Alliance for Traditional Chinese Patent Medicine Pills and the Ma’anshan Engineering Technology Center. Its preclinical echinacoside Alzheimer’s project received approval under the Ministry of Science and Technology’s 12th Five-Year Plan. Building on its expertise in Traditional Chinese Medicine, the company plans to add a 10,000 sq.m. biotech drug base and 12,000 sq.m. chemical drug workshops to support 2–3 annual Hubble Kisen R&D transfers, ultimately creating an industrial park exceeding 80,000 m² for patent medicines, chemical drugs, and biologics.
External Medicines -- Guangdong Taienkang Pharmaceutical Factory Co., Ltd.
Guangdong Taienkang Pharmaceutical Factory Co., Ltd., originally Shantou Wuhuan Pharmaceutical Factory established in the 1950s, is now a Guangdong high-tech enterprise occupying over 10,000 m²—including a 7,000 m² GMP-compliant workshop, a 2,500 sq.m office, and 120+ advanced production and testing units—focused on professional external-use medicines. It manufactures six dosage forms (liniments, rubber pastes, ointments, inhalants, creams, lotions) across more than 20 products with 16 drug registrations, and its flagship “Wuhuan” brand captured an 11.4% market share in 2016—ranking second nationally and earning a strong reputation in China and Southeast Asian Chinese markets. The company has been honored as a Guangdong Private Science and Technology Enterprise, a Price Measurement Reliable Enterprise, and a “Love Enterprise” for its contributions to health poverty alleviation.
Biotechnology -- Guangdong T&K Biotechnology Co., Ltd.
T&K Biotechnology, a wholly owned subsidiary of Guangdong Taienkang Pharmaceutical, operates an 8,000 sq.m GMP-compliant facility for medical devices and daily hygiene products, equipped with general areas, 100,000-level clean zones, 10,000/100-level microbiology labs, and general laboratories. It holds Medical Device Manufacturing and Disinfection Product licenses from Guangdong authorities, is certified to ISO 13485:2016 and ISO 9001:2015, and strictly adheres to the medical device GMP quality management system. Recognized as a private technology enterprise in Shantou and a Guangdong high-tech enterprise, T&K boasts 3 invention patents, 45 additional patents, and multiple “High-tech Technical Product” awards. Its commercialization of Class III products—microsphere polylactic acid implants and Immune Age Diagnostic Kits—has brought new momentum to its high-quality development.
T&K Europe
T&K Europe have arrived. We are a wholly owned subsidiary of Guangdong Taienkang Pharmaceutical Co., Ltd based in Shantou, China. Our parent company are stock listed with an annual turnover exceeding $84 Million. Since the start of the Covid-19 Global Pandemic, T&K have sold over 200 million masks and invested in a European base in London with a state-of-the-art logistics warehouse in Oxfordshire.
Future Strategy
T&K commits to strengthening five major product lines (Gastroenterology, Ophthalmology, Gender, Dermatology and Anti-aging) through endogenous R&D and strategic expansions, positioning itself as an innovation-driven leader in healthcare.
Featured Video
BEHIND THE MASK
Watch the science behind T&K masks
T&K FACTORY TOUR
Watch the tour of a T&K China Factory
CORPORATE VIDEO
Watch the latest T&K Corporate Video